top of page
< Back

Bosutinib

博舒替尼

Mechanism of action:

Bosutinib 是一種口服型酪胺酸激酶抑制劑（tyrosine kinase inhibitor）。在帶有染色體易位 t(9;22)(q34;q11) 產生 BCR-ABL 融合基因的細胞模型中，生成可持續活化的 ABL 酪胺酸激酶。Bosutinib 直接結合 BCR-ABL 激酶的 ATP 結合位點，抑制下游訊息傳導途徑，阻斷細胞增殖與影響細胞存活相關路徑。

​Reference(s):

1. Amsberg GK et al. (2013). Bosutinib in the management of chronic myelogenous leukemia. Biologics. 


2. Keller-V Amsberg G et al. (2012). Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia. Expert Rev Anticancer Ther.

bottom of page